711P Nivolumab + ipilimumab (N+I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of pati... von Albiges, L., Tannir, N., Burotto, M., McDermott, D.F., Plimack, E.R., Barthélémy, P., Porta, C.G., Powles, T.B., Donskov, F., George, S., Kollmannsberger, C., Gurney, H., Grimm, M-O., Tomita, Y., Castellano Gauna, D., Rini, B.I., Choueiri, T.K., Saggi, S.S., McHenry, M.B., Motzer, R.J.

Volltext

Assessment of nivolumab benefit–risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors von Zhao, X., Suryawanshi, S., Hruska, M., Feng, Y., Wang, X., Shen, J., Vezina, H.E., McHenry, M.B., Waxman, I.M., Achanta, A., Bello, A., Roy, A., Agrawal, S.

Volltext

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study von Slovin, S.F., Higano, C.S., Hamid, O., Tejwani, S., Harzstark, A., Alumkal, J.J., Scher, H.I., Chin, K., Gagnier, P., McHenry, M.B., Beer, T.M.

Volltext

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma von Motzer, Robert J, Tannir, Nizar M, McDermott, David F, Arén Frontera, Osvaldo, Melichar, Bohuslav, Choueiri, Toni K, Plimack, Elizabeth R, Barthélémy, Philippe, Porta, Camillo, George, Saby, Powles, Thomas, Donskov, Frede, Neiman, Victoria, Kollmannsberger, Christian K, Salman, Pamela, Gurney, Howard, Hawkins, Robert, Ravaud, Alain, Grimm, Marc-Oliver, Bracarda, Sergio, Barrios, Carlos H, Tomita, Yoshihiko, Castellano, Daniel, Rini, Brian I, Chen, Allen C, Mekan, Sabeen, McHenry, M. Brent, Wind-Rotolo, Megan, Doan, Justin, Sharma, Padmanee, Hammers, Hans J, Escudier, Bernard

Volltext

Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies von Lebbé, C., Weber, J.S., Maio, M., Neyns, B., Harmankaya, K., Hamid, O., O'Day, S.J., Konto, C., Cykowski, L., McHenry, M.B., Wolchok, J.D.

Volltext

139MO Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC... von Xu, R-H., Oh, D-Y., Kato, K., Arkenau, H-T., Tabernero, J., Cruz-Correa, M., Zimina, A.V., Bai, Y., Shi, J., Lee, K-W., Hirano, H., Spigel, D.R., Wyrwicz, L.S., Pazo Cid, R.A., Li, L., Xu, Y., McHenry, M.B., Yang, S., Moehler, M.

Volltext

LBA80 Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC... von Xu, R-H., Oh, D-Y., Kato, K., Arkenau, T., Tabernero, J., Cruz-Correa, M., Zimina, A., Bai, Y., Shi, J., Lee, K-W., Hirano, H., Spigel, D.R., Wyrwicz, L.S., Pazo Cid, R.A., Li, L., Xu, Y., McHenry, M.B., Yang, S., Moehler, M.

Volltext

661P Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC) von Motzer, R.J., Tannir, N.M., McDermott, D.F., Burotto, M., Choueiri, T.K., Hammers, H.J., Plimack, E.R., Porta, C.G., George, S., Powles, T.B., Donskov, F., Gurney, H., Kollmannsberger, C.K., Grimm, M-O., Tomita, Y., Rini, B.I., McHenry, M.B., Lee, C-W., Escudier, B.

Volltext

A phase III, randomized, placebo-controlled trial of adjuvant nivolumab plus ipilimumab in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse... von Bex, A., Grünwald, V., Russo, P., Tomita, Y., Berghorn, E., McHenry, M.B., Motzer, R.J.

Volltext

Association between depth of response and overall survival: Exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 214 von Grünwald, V., Choueiri, T.K., Rini, B.I., Powles, T., George, S., Grimm, M.-O., McHenry, M.B., Maurer, M., Motzer, R.J., Hammers, H.J., Tannir, N.M., Albiges, L.

Volltext

950P - Association between depth of response and overall survival: Exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 214 von Grünwald, V., Choueiri, T.K., Rini, B.I., Powles, T., George, S., Grimm, M.-O., McHenry, M.B., Maurer, M., Motzer, R.J., Hammers, H.J., Tannir, N.M., Albiges, L.

Volltext

Characterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214 von Rini, B.I., Tannir, N.M., Escudier, B., McDermott, D.F., Grimm, M.-O., Porta, C., Powles, T., Kollmannsberger, C.K., Gurney, H.P., Tykodi, S.S., Harrison, M., Heng, D.Y.C., Grünwald, V., Choueiri, T.K., Mekan, S., McHenry, M.B., Hammers, H.J., Motzer, R.J., George, S.

Volltext

CheckMate 214: Efficacy and safety of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naïve advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and P... von Escudier, B., Tannir, N.M., McDermott, D.F., Frontera, O.A., Melichar, B., Plimack, E.R., Barthelemy, P., George, S., Neiman, V., Porta, C., Choueiri, T.K., Powles, T., Donskov, F., Salman, P., Kollmannsberger, C.K., Rini, B., Mekan, S., McHenry, M.B., Hammers, H.J., Motzer, R.J.

Volltext

763PDUPDATED OVERALL SURVIVAL (OS) FROM THE PHASE 3 TRIAL, CA184-043: IPILIMUMAB (IPI) VS PLACEBO (PBO) IN PATIENTS WITH POST-DOCETAXEL METASTATIC CASTRATION-RESISTANT PROSTATE CAN... von Fizazi, K., Drake, C.G., Kwon, E.D., Bossi, A., van den Eertwegh, A.J., Scher, H.I., Beer, T.M., McHenry, M.B., Liu, D., Gerritsen, W.R., Logothetis, C.

Volltext

Updated Overall Survival (Os) from the Phase 3 Trial, Ca184-043: Ipilimumab (Ipi) Vs Placebo (Pbo) in Patients with Post-Docetaxel Metastatic Castration-Resistant Prostate Cancer (... von Fizazi, K., Drake, C.G., Kwon, E.D., Bossi, A., van den Eertwegh, A.J., Scher, H.I., Beer, T.M., McHenry, M.B., Liu, D., Gerritsen, W.R., Logothetis, C.

Volltext

Five-Year Survival Rates for Patients (PTS) with Metastatic Melanoma (MM) Treated with Ipilimumab (IPI) in Phase II Trials von Lebbe, C., Weber, J.S., Maio, M., Neyns, B., Harmankaya, K., Chin, K., McDowell, D. Opatt, Cykowski, L., McHenry, M.B., Wolchok, J.D.

Volltext

1116PD - Five-Year Survival Rates for Patients (PTS) with Metastatic Melanoma (MM) Treated with Ipilimumab (IPI) in Phase II Trials von Lebbe, C., Weber, J.S., Maio, M., Neyns, B., Harmankaya, K., Chin, K., McDowell, D. Opatt, Cykowski, L., McHenry, M.B., Wolchok, J.D.

Volltext

Caractérisation de la réponse au traitement par nivolumab plus ipilimumab (N+I) ou sunitinib (S) chez des patients (pts) atteints d’un carcinome à cellules rénales avancé (CCRa) no... von Rini, B.I., Tannir, N.M., Escudier, B., McDermott, D.F., Grimm, M.-O., Porta, C., Powles, T., Kollmannsberger, C., Gurney, H., Tykodi, S.S., Harrison, M., Heng, D.Y.C., Grünwald, V., Choueri, T.K., Mekan, S., McHenry, M.B., Hammers, H.J., Motzer, R.J., George, S.

Volltext

PT128 - Post-nephrectomy adjuvant therapy for localized renal cell carcinoma (RCC): The phase III randomized, placebo-controlled CheckMate 914 study of nivolumab plus ipilimumab in... von Bex, A., Russo, P., Tomita, Y., Grunwald, V., Ramirez, L.M., McHenry, M.B., Motzer, R.J.

Volltext

Post-nephrectomy adjuvant therapy for localized renal cell carcinoma (RCC): The phase III randomized, placebo-controlled CheckMate 914 study of nivolumab plus ipilimumab in patient... von Bex, A., Russo, P., Tomita, Y., Grunwald, V., Ramirez, L.M., McHenry, M.B., Motzer, R.J.

Volltext